ATE424384T1 - Imidazolderivate, verfahren zu deren herstellung und deren anwendungen - Google Patents

Imidazolderivate, verfahren zu deren herstellung und deren anwendungen

Info

Publication number
ATE424384T1
ATE424384T1 AT04819628T AT04819628T ATE424384T1 AT E424384 T1 ATE424384 T1 AT E424384T1 AT 04819628 T AT04819628 T AT 04819628T AT 04819628 T AT04819628 T AT 04819628T AT E424384 T1 ATE424384 T1 AT E424384T1
Authority
AT
Austria
Prior art keywords
imidazole derivatives
applications
production
pharmaceuticals
preparing
Prior art date
Application number
AT04819628T
Other languages
English (en)
Inventor
Benoit Kenda
Philippe Michel
Yannick Quesnel
Original Assignee
Ucb Pharma Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ucb Pharma Sa filed Critical Ucb Pharma Sa
Application granted granted Critical
Publication of ATE424384T1 publication Critical patent/ATE424384T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/24—Oxygen or sulfur atoms
    • C07D207/26—2-Pyrrolidones
    • C07D207/263—2-Pyrrolidones with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to other ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/24—Oxygen or sulfur atoms
    • C07D207/26—2-Pyrrolidones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/24—Oxygen or sulfur atoms
    • C07D207/26—2-Pyrrolidones
    • C07D207/263—2-Pyrrolidones with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to other ring carbon atoms
    • C07D207/27—2-Pyrrolidones with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to other ring carbon atoms with substituted hydrocarbon radicals directly attached to the ring nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/08—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing alicyclic rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Addiction (AREA)
  • Vascular Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Urology & Nephrology (AREA)
  • Immunology (AREA)
  • Otolaryngology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Epoxy Resins (AREA)
  • Macromolecular Compounds Obtained By Forming Nitrogen-Containing Linkages In General (AREA)
AT04819628T 2003-12-02 2004-11-29 Imidazolderivate, verfahren zu deren herstellung und deren anwendungen ATE424384T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP03027614 2003-12-02

Publications (1)

Publication Number Publication Date
ATE424384T1 true ATE424384T1 (de) 2009-03-15

Family

ID=34639269

Family Applications (1)

Application Number Title Priority Date Filing Date
AT04819628T ATE424384T1 (de) 2003-12-02 2004-11-29 Imidazolderivate, verfahren zu deren herstellung und deren anwendungen

Country Status (16)

Country Link
US (2) US7244747B2 (de)
EP (2) EP2050736A1 (de)
JP (1) JP2007513105A (de)
KR (1) KR20060110349A (de)
CN (1) CN1906160A (de)
AT (1) ATE424384T1 (de)
AU (1) AU2004295083B2 (de)
BR (1) BRPI0417157A (de)
CA (1) CA2546970C (de)
DE (1) DE602004019814D1 (de)
EA (1) EA010031B1 (de)
ES (1) ES2323313T3 (de)
MX (1) MXPA06006026A (de)
NO (1) NO20063062L (de)
WO (1) WO2005054188A1 (de)
ZA (1) ZA200604410B (de)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE533853T1 (de) * 2004-02-24 2011-12-15 Allergan Inc Botulinumtoxin-screening-assays
AU2006254335A1 (en) * 2005-06-01 2006-12-07 Ucb Pharma, S.A. 2-oxo-1-pyrrolidine derivatives and their therapeutic use on the central nervous system
WO2007031263A1 (en) * 2005-09-15 2007-03-22 Ucb Pharma, S.A. 4-substituted pyrr0lidin-2-0nes and their use
KR101404360B1 (ko) 2006-09-05 2014-06-09 교와 핫꼬 기린 가부시키가이샤 이미다졸 유도체
EP2152262A2 (de) * 2007-04-27 2010-02-17 UCB Pharma, S.A. Neue heterocyclische derivate zur behandlung von zns-erkrankungen
EP2017273A1 (de) * 2007-07-18 2009-01-21 Laboratorios del Dr. Esteve S.A. Verfahren zur enantioselektiven Herstellung von Pregabalin
US7883745B2 (en) * 2007-07-30 2011-02-08 Micron Technology, Inc. Chemical vaporizer for material deposition systems and associated methods
WO2009132238A2 (en) 2008-04-24 2009-10-29 Newlink Genetics Ido inhibitors
JP5917148B2 (ja) * 2008-10-16 2016-05-11 ザ ジョーンズ ホプキンズ ユニバーシティＴｈｅ Ｊｏｈｎｓ Ｈｏｐｋｉｎｓ Ｕｎｉｖｅｒｓｉｔｙ 認知機能を改善するための方法および組成物
EP2461808A2 (de) 2009-08-07 2012-06-13 UCB Pharma S.A. Verfahren zur verbesserung der kognitiven funktion
WO2011047860A1 (en) 2009-10-23 2011-04-28 Ucb Pharma, S.A. 2-oxo-1-pyrrolidinyl imidazothiadiazole derivatives
EA037187B1 (ru) 2010-02-09 2021-02-17 Дзе Джонс Хопкинс Юниверсити Способ и композиция для лечения когнитивного расстройства
US8680098B2 (en) 2010-03-05 2014-03-25 Janssen Pharmaceutica, Nv Substituted aza-bicyclic imidazole derivatives useful as TRPM8 receptor modulators
HUE026889T2 (en) 2011-04-18 2016-07-28 Ucb Biopharma Sprl 2-Oxo-1-imidazolidinyl derivatives imidazotiadiazol
WO2014012563A1 (en) * 2012-07-20 2014-01-23 Ucb Pharma, S.A. Compounds for enhancing the cognitive function
WO2014078568A1 (en) 2012-11-14 2014-05-22 The Johns Hopkins University Methods and compositions for treating schizophrenia
US11160785B2 (en) 2013-03-15 2021-11-02 Agenebio Inc. Methods and compositions for improving cognitive function
US10806717B2 (en) 2013-03-15 2020-10-20 The Johns Hopkins University Methods and compositions for improving cognitive function
KR20220038826A (ko) 2014-01-21 2022-03-29 얀센 파마슈티카 엔.브이. 대사 조절형 글루탐산 작동성 수용체 제2아형의 양성 알로스테릭 조절제 또는 오르토스테릭 작동제를 포함하는 조합 및 그 용도
KR20200036063A (ko) 2014-01-21 2020-04-06 얀센 파마슈티카 엔.브이. 대사 조절형 글루탐산 작동성 수용체 제2아형의 양성 알로스테릭 조절제 또는 오르토스테릭 작동제를 포함하는 조합 및 그 용도
RU2654065C1 (ru) * 2017-03-16 2018-05-16 Федеральное государственное бюджетное образовательное учреждение высшего образования "Уфимский государственный нефтяной технический университет" Способ получения N-оксиметиламинов
CN106866494A (zh) * 2017-03-20 2017-06-20 安徽金鼎医药股份有限公司 一种格列齐特中间体八氢环戊烷并[c]吡咯的制备方法
IL319072A (en) 2022-08-19 2025-04-01 Agenebio Inc History of Benzazepine, Compositions and Methods for Treating Cognitive Impairment

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3903110A (en) 1972-04-27 1975-09-02 Gaf Corp N-(2-pyrrolidinonyl) methyl carbamate derivatives
AT352119B (de) * 1975-07-29 1979-09-10 Celamerck Gmbh & Co Kg Verfahren zur herstellung neuer imidazol-bzw. triazolderivate
GB1582351A (en) * 1977-02-10 1981-01-07 Ucb Sa Disubstituted ureas and thioureas
US4178167A (en) * 1977-06-16 1979-12-11 Gaf Corporation Herbicidal N-(haloacetyl)-N-(N'-methylenepyrrolidonyl)-2-alkoxyanilines useful as herbicides
GB8412357D0 (en) 1984-05-15 1984-06-20 Ucb Sa Pharmaceutical composition
GB8412358D0 (en) 1984-05-15 1984-06-20 Ucb Sa Pharmaceutical composition
AU2869092A (en) * 1991-10-11 1993-05-03 Smithkline Beecham Corporation Heterocyclic 3-phenylpyrrolidin-2-ones, their preparation and use for the manufacture of a medicament for inhibiting tumor necrosis factor production
JPH06220044A (ja) * 1991-12-25 1994-08-09 Mitsubishi Kasei Corp ベンズアミド誘導体
JP2000508319A (ja) * 1996-04-10 2000-07-04 メルク エンド カンパニー インコーポレーテッド αｖβ３拮抗薬
GB0004297D0 (en) * 2000-02-23 2000-04-12 Ucb Sa 2-oxo-1 pyrrolidine derivatives process for preparing them and their uses

Also Published As

Publication number Publication date
EP1706376A1 (de) 2006-10-04
CA2546970C (en) 2011-04-26
BRPI0417157A (pt) 2007-03-06
EA200601065A1 (ru) 2006-12-29
ZA200604410B (en) 2008-09-25
US20050137241A1 (en) 2005-06-23
CN1906160A (zh) 2007-01-31
WO2005054188A1 (en) 2005-06-16
US20080081832A1 (en) 2008-04-03
US7244747B2 (en) 2007-07-17
US7763644B2 (en) 2010-07-27
MXPA06006026A (es) 2006-08-23
EP1706376B1 (de) 2009-03-04
JP2007513105A (ja) 2007-05-24
KR20060110349A (ko) 2006-10-24
EP2050736A1 (de) 2009-04-22
ES2323313T3 (es) 2009-07-13
NO20063062L (no) 2006-08-30
EA010031B1 (ru) 2008-06-30
AU2004295083B2 (en) 2010-08-19
CA2546970A1 (en) 2005-06-16
AU2004295083A1 (en) 2005-06-16
DE602004019814D1 (de) 2009-04-16

Similar Documents

Publication Publication Date Title
ATE424384T1 (de) Imidazolderivate, verfahren zu deren herstellung und deren anwendungen
ATE482194T1 (de) Indolonderivate, verfahren zu deren herstellung und deren anwendungen
ATE433447T1 (de) Pyrimiidinverbindungen
ATE401304T1 (de) Kationisch substituierte diphenylazetidinone, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
DE50307267D1 (de) Dihydropteridinone, verfahren zu deren herstellung und deren verwendung als arzneimittel
CA2495967A1 (fr) Nouveau procede de synthese et nouvelle forme cristalline de l'agomelatine ainsi que les compositions pharmaceutiques qui la contiennent
SE0301010D0 (sv) Novel compounds
TW200732323A (en) Organic compounds
SE0200920D0 (sv) Novel compounds
CY1110115T1 (el) Παραγωγα ακετυλενυλο-πυραζολο-πυριμιδινης ως mglur2 ανταγωνιστες
SE0301009D0 (sv) Novel compounds
TW200833326A (en) Chemical compounds 572
ATE514692T1 (de) Phenothiazin derivate, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel
TNSN04250A1 (en) Diphenyl azetidinones substituted by acidic groups, method for their production, medicaments containing said compounds and use thereof.
SE0401762D0 (sv) Novel compounds
ES2335410T8 (es) Derivados de aminopropanol.
SE0302139D0 (sv) Novel compounds
ATE347555T1 (de) 6-aminomorphinanderivate, herstellungsverfahren dafür und deren verwendung
JO2734B1 (en) Organic compounds
TNSN07395A1 (en) Novel phenyl-pyridinyl-piperazine derivatives, a method for the production thereof and pharmaceutical compositions containing said derivatives
DE50311923D1 (de) Harnstoff- und urethan-substituierte acylharnstoffe, verfahren zu deren herstellung und deren verwendung als arzneimittel
TW200714598A (en) Urea derivatives, methods for their manufacture, and uses therefor
SE0303280D0 (sv) Novel compounds
ATE517900T1 (de) Heptarylen-und octarylentetracarbonsäurediimide und deren herstellung
ATE386735T1 (de) Substituierte benzoylureidopyridyl-piperidin- und pyrrolidin-carbons urederivate, verfahren zu deren herstellung und deren v erwendung

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties